{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.062","value":"-0.374"},{"groupId":"OG001","spread":"5.663","value":"0.384"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"436"},{"groupId":"OG001","value":"432"}],"units":"Participants"}],"title":"Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.968","value":"0.053"},{"groupId":"OG001","spread":"5.978","value":"-0.149"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"347"}],"units":"Participants"}],"title":"Day 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.994","value":"-0.271"},{"groupId":"OG001","spread":"5.387","value":"0.351"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"230"}],"units":"Participants"}],"title":"Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.779","value":"0.622"},{"groupId":"OG001","spread":"7.283","value":"0.309"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"title":"Day 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.352","value":"-0.988"},{"groupId":"OG001","spread":"6.579","value":"-0.422"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"230"}],"units":"Participants"}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.229","value":"0.774"},{"groupId":"OG001","spread":"10.386","value":"-0.219"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"206"}],"units":"Participants"}],"title":"Day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"436"},{"groupId":"OG001","value":"432"}],"units":"Participants"}],"description":"Blood to evaluate d-dimer concentration was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","dispersionType":"Standard Deviation","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"MEAN","populationDescription":"The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.","reportingStatus":"POSTED","timeFrame":"Days 1, 3, 5, 8, 11, 15 and 29","title":"Change From Baseline in D-dimer Concentration","type":"SECONDARY","unitOfMeasure":"mg/L"}